Search

A series of stereospecific conjugates of the naturally occurring scaffold - alkaloid securinine 1 - was synthesized using the Lewis acid catalyst ytterbium triflate. The study of their antioxidant and cytoprotective properties showed that these compounds can be considered as potential neuroprotectors. Among these compounds, a leader substance is identified - securinine conjugate with tryptamine. Further research has confirmed that this compound is capable to protecting neuronal cells from the toxic effects of glutamate and iron ions. Based on these results, derivatives of securinine scaffold are promising compounds for development of new drugs for the treatment of neurodegenerative diseases.A series of stereospecific conjugates of the naturally occurring scaffold - alkaloid securinine 1 - was synthesized using the Lewis acid catalyst ytterbium triflate. The study of their antioxidant and cytoprotective properties showed that these compounds can be considered as potential neuroprotectors. Among these compounds, a leader substance is identified - securinine conjugate with tryptamine. Further research has confirmed that this compound is capable to protecting neuronal cells from the toxic effects of glutamate and iron ions. Based on these results, derivatives of securinine scaffold are promising compounds for development of new drugs for the treatment of neurodegenerative diseases.

The reaction of DL-valine hydroxamic acid with triacetonamine passes as N, N′-regioselective cyclocondensation to form (±) -1-hydroxy-3-isopropyl-7,7,9,9-tetramethyl-1,4,8-triazaspiro [4.5] decan-2-one. In vivo study of chemosensitizing antitumor activity of spirocyclic hydroxamic acid by the combination therapy with cytostatics of alkylating type cisplatin and cyclophosphamide in the model of leukemia P388 was investigated. It was shown the ability of this acid to increase the sensitivity of the tumor to the action of cisplatin and cyclophosphamide applied at doses below therapeutic. Chemosensitizing activity of spirocyclic hydroxamic acid has made it possible to achieve an appreciable level of survival of tumor-bearing animals (up to 37.5%).